SP
SPRO.US Spero Therapeutics Inc
- Market cap
- USD 52.4M
- P/E
- -
- P/B
- 74.39x
- ROE
- -10,419.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SPRO.US undervalued?
Graham numberThe Graham number of Spero Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spero Therapeutics Inc fundamental analysis
No fundamental analysis for Spero Therapeutics Inc yet.
Spero Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It …
Full company profileSpero Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spero Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 335K | 1.98M | 3.97M | 4.74M | 9.33M | 3.07M | 48.6M | 104M | 48.0M | 59.6M | 344K |
| Gross Profit | -26.0M | 1.98M | 3.97M | 4.74M | 9.33M | 3.07M | 48.6M | 52.3M | -48.8M | 59.6M | - |
| Operating Income | -33.2M | -41.7M | -42.8M | -63.2M | -79.1M | -88.0M | -42.2M | 21.5M | -73.4M | -24.0K | -32.5M |
| EBITDA | -32.9M | -41.4M | -42.4M | -62.5M | -78.4M | -87.2M | -42.9M | 27.2M | -72.5M | 8.83M | -31.6M |
| Net Income | -25.5M | -46.1M | -41.7M | -60.2M | -77.5M | -89.8M | -46.4M | 22.8M | -68.6M | 8.57M | -81.4M |
| EPS | -3.86 | -18 | -2.60 | -3.31 | -3.46 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -1.40 |
| Balance Sheet | |||||||||||
| Total Assets | 13.8M | 93.5M | 129M | 106M | 153M | 171M | 125M | 182M | 111M | 68.9M | 110M |
| Total Liabilities | 7.41M | 8.52M | 13.2M | 31.5M | 21.4M | 82.8M | 48.9M | 75.5M | 64.4M | 9.90M | 109M |
| Shareholders' Equity | 10.2M | 85.0M | 116M | 74.6M | 132M | 88.3M | 75.9M | 107M | 46.1M | 59.0M | 781K |
| Cash & Short-term Investments | 10.3M | 87.3M | 115M | 82.0M | 127M | 146M | 109M | 76.3M | 52.9M | 40.3M | 108M |
| Total Debt | - | - | - | 5.55M | 7.84M | 7.34M | 6.65M | 5.54M | 4.30M | 2.90M | 1.59M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.0M | -39.1M | -39.6M | -50.0M | -85.9M | -64.3M | -7.73M | -33.0M | -23.4M | -12.6M | -42.8M |
| Capital Expenditure | 830K | 27.0K | 2.44M | 314K | 157K | 64.3M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -29.8M | -39.1M | -42.1M | -50.3M | -86.0M | -64.3M | -7.73M | -33.0M | -23.4M | -12.6M | -42.8M |
| Ratios | |||||||||||
| ROE | -250.7% | -54.3% | -36.0% | -80.7% | -58.7% | -101.7% | -61.1% | 21.3% | -148.7% | 14.5% | -10,419.6% |
| ROA | -185.1% | -49.3% | -32.3% | -56.7% | -50.5% | -52.5% | -37.2% | 12.5% | -62.0% | 12.4% | -74.0% |
| Net Profit Margin | -7,609.3% | -2,329.3% | -1,050.5% | -1,269.0% | -830.9% | -2,923.6% | -95.5% | 22.0% | -142.9% | 14.4% | -23,656.2% |
| Debt to Equity | - | - | - | 0.07x | 0.06x | 0.08x | 0.09x | 0.05x | 0.09x | 0.05x | 2.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Spero Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 54.5M | 1.45 | - |
| 2021 | USD 47.5M | 1.54 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Spero Therapeutics Inc
- Insiders 22.58%
- Institutions 26.27%
- Public & others 51.15%
- Shares outstanding 58.3M
- Free float 47.1M
Top funds holding SPRO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.40M | 2.40% | 0.00% | Sep 2026 |
| Mackenzie GQE US Small Cap F8 | 497K | 0.85% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 217K | 0.37% | +202.28% | Sep 2026 |
| iShares Micro-Cap ETF | 137K | 0.24% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 108K | 0.19% | 0.00% | Sep 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 96.5K | 0.17% | +1.92% | Oct 2026 |
| Fidelity Series Total Market Index | 69.8K | 0.12% | 0.00% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 66.8K | 0.11% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 63.1K | 0.11% | 0.00% | Oct 2026 |
| Acuitas US Microcap Institutional | 56.5K | 0.10% | 0.00% | Jun 2026 |
| Bridgeway Omni Small-Cap Value N | 50.0K | 0.09% | 0.00% | Jun 2026 |
| Dimensional Global Trgtd Value USD Acc | 32.1K | 0.06% | -0.41% | Sep 2026 |
| Schwab Total Stock Market Index | 28.6K | 0.05% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 25.4K | 0.04% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 24.2K | 0.04% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 22.8K | 0.04% | 0.00% | Sep 2026 |
| Dimensional VA US Targeted Value | 15.1K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 10.2K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding SPRO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| GSK PLC | 9.19M | 15.78% | 0.00% | Jun 2026 |
| Pfizer Inc | 2.36M | 4.06% | 0.00% | Sep 2026 |
| Vanguard Capital Management, LLC | 2.04M | 3.50% | +13.13% | Jun 2026 |
| Renaissance Technologies Corp | 1.41M | 2.42% | +48.73% | Sep 2026 |
| Alphabet Inc | 890K | 1.53% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 759K | 1.30% | +127.94% | Jun 2026 |
| BlackRock Inc | 594K | 1.02% | +37.21% | Jun 2026 |
| Geode Capital Management, LLC | 566K | 0.97% | +8.93% | Jun 2026 |
| Two Sigma Investments LLC | 383K | 0.66% | -56.78% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 333K | 0.57% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 288K | 0.49% | +8.91% | Jun 2026 |
| GSA Capital Partners LLP | 286K | 0.49% | +2.73% | Jun 2026 |
| The Goldman Sachs Group Inc | 257K | 0.44% | 0.00% | Jun 2026 |
| State Street Corp | 215K | 0.37% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 158K | 0.27% | +48.66% | Jun 2026 |
| UBS Group AG | 140K | 0.24% | +4,542.07% | Jun 2026 |
| Bridgeway Capital Management, LLC | 115K | 0.20% | 0.00% | Jun 2026 |
| Northern Trust Corp | 108K | 0.19% | -10.51% | Jun 2026 |
| Point72 Asset Management, L.P. | 104K | 0.18% | +74.93% | Jun 2026 |
| Ionic Capital Management LLC | 103K | 0.18% | -47.59% | Jun 2026 |
Spero Therapeutics Inc company profile
- Company name
- Spero Therapeutics Inc
- Ticker
- SPRO.US
- Exchange
- USA Stocks
- Listed since
- Nov 2, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25
- Fiscal year end
- December
- Address
- 675 Massachusetts Avenue, Cambridge, MA, United States, 02139
- Phone
- 857 242 1600
- Website
- sperotherapeutics.com
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics Inc management
7- Ms. Esther P. RajaveluCEO, President, CFO, Chief Business Officer, Treasurer & Director · born 1979
- Mr. Timothy KeutzerChief Operating Officer · born 1968
- Mr. John RaymondSenior Vice President of Finance & Business Operations
- Dr. Debra Jeske Zack M.D., Ph.D.Chief Medical Officer · born 1957
- Dr. Amy Dix Rock Ph.D.Chief Regulatory & Quality Officer · born 1971
- Dr. Dae Gon Ha Ph.D.Senior Vice President of Corporate Development
- Ms. Sheila FinanSenior VP & Controller